The epidemiologic burden of hepatitis C virus infection in Latin America
Journal Title: Annals of Hepatology - Year 2012, Vol 11, Issue 5
Abstract
Chronic infection with hepatitis C virus (HCV) is a major and growing public health concern worldwide, including in Latin America. With more efficacious therapies becoming available, decision-makers will require accurate estimates of disease prevalence to assess the potential impact of new treatments. However, few estimates of the epidemiologic burden, either overall or by country, are available for Latin America; and the potential impact of currently-available treatments on the epidemiologic burden of HCV in Latin America has not been assessed. To address this, we systematically reviewed twenty-five articles presenting population-based estimates of HCV prevalence from general population or blood donor samples, and supplemen-ted those with publically-available data, to estimate the total number of persons infected with HCV in Latin America at 7.8 million (2010). Of these, over 4.6 million would be expected to have genotype 1 chronic HCV, based on published data on the risk of progression to chronic disease and the HCV genotype distribution of Latin America. Finally, we calculated that between 1.6 and 2.3 million persons with genotype 1 chronic HCV would potentially benefit from current treatments, based on published estimates of genotype-specific treatment responsiveness. In conclusion, these estimates demonstrate the substantial present epidemiologic burden of HCV, and quantify the impending societal and clinical burden from untreated HCV in Latin America.
Authors and Affiliations
Shelagh Szabo, Meagan Bibby, Yong Yuan, Bonnie Donato, R. Jiménez-Mendez, Maribel Rodríguez-Torres, G. Castañeda-Hernández, Adrian Levy
Keywords
Related Articles
- EP ID EP78183
- DOI -
- Views 123
- Downloads 0
Pegylated interferon, but not conventional interferon therapy induced severe skin lesions
Embolization of porto-systemic shunt as treatment for recurrent hepatic encephalopathy
Hemodynamic effect of carvedilol vs. propranolol in cirrhotic patients: Systematic review and meta-analysis
Background. Carvedilol appears to be more effective than propranolol in the treatment of portal hypertension in cirrhotic patients. Aim. To compare the effects of carvedilol vs. propranolol on systemic and splanchnic hae...
The limited prognostic value of liver histology in children with biliary atresia
Background and rationale for the study. The aim of the study was to determine the prognostic value of histopathological findings with special care to the severity of liver fibrosis at the moment of hepatoportoenterostomy...
Recreational Drug and Psychosocial Profile in Chronic Hepatitis C Patients Seeking Antiviral Therapy
Background and aims. Practitioners treating hepatitis C (HCV) provide healthcare to a special population with high rates of substance abuse and psychiatric disorders. We investigated the psychosocial profile in HCV patie...